Peanut allergy trial welcomes first patients

Do you have a peanut allergy? 

Monash Health recently welcomed the first trial patients, Nila and Isabella, for a new medication to treat peanut allergies.  

In Australia, approximately 3 in 100 infants suffer from peanut allergies. While research shows that by age six, about 30% of children outgrow their peanut allergy, it’s still one of the common food allergies affecting adults.  

An allergy to peanuts can be life-threatening, with an exposure possibly leading to a severe allergic reaction known as anaphylaxis. 

Currently, there is no cure for food allergies. The only way to prevent an allergic reaction is to strictly avoid the food a person is allergic to. 

Now, a potentially groundbreaking medication that promises to block one’s allergic responses upon exposure to allergens like peanuts is taking place at Monash Health, Fiona Stanley Hospital, St Vincent’s Hospital, and The Royal Melbourne Hospital. 

The Phase 1 trial is evaluating the medication known as IGNX001’s safety and tolerability through a placebo-controlled, randomised, double-blind study in peanut-allergic individuals. 

For more information about the trial, you can read more at Peanut allergy trial recruits adolescents and adults – raising hope